Among the novel limbic lobe encephalitis (LE), there is a relatively rare group of diseases, leucine-rich glioma inactivation 1 protein antibody-mediated LE. LGI1 antibody-mediated LE is an autoimmune encephalitis that starts after middle age, with an age of onset of 30-80 years (mean 60 years) and a relative prevalence in men. The main clinical manifestations are rapidly progressive near-memory loss, psychiatric abnormalities, and seizures. In addition to this, there can be autonomic dysfunction (abnormal sweating, urinary and bowel disorders, abnormal blood pressure/heart rate, etc.), and sleep disturbances. Facioscapulohumeral dystonic epilepsy (a specific form of epilepsy that manifests as rapid shaking of the ipsilateral face/upper limbs) and intractable hyponatremia are characteristic and diagnostically suggestive. LGI1 antibody-mediated LE is a relatively benign disease with rare recurrences, which is more effective with immunotherapy such as hormones, and can generally be clinically cured if diagnosed early and treated appropriately.